A lawsuit filed in the Singapore International Commercial Court is seeking $830 million in damages from KBP, with Novo ...

Pfizer's strong Q4 2024 results showcase growth in cancer drugs and Vyndaqel sales. Learn why PFE stock is a top pick for ...

Royalty Pharma plc (Nasdaq: RPRX) today announced that it has entered into an agreement with Biogen to provide research and development (R&D) funding of up ...

We are excited to collaborate with Biogen on litifilimab,” said Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer. “Royalty Pharma offers tailored, win-win funding solutions for ...

Fintel reports that on February 11, 2025, Deutsche Bank initiated coverage of Biohaven (NYSE:BHVN) with a Buy recommendation.

Ubrelvy (ubrogepant) and Nurtec (rimegepant) are prescription medications approved to help manage and offer relief for people dealing with migraine headaches with or without aura. Both belong to a ...

Louis, Missouri. "Good Morning America" got an exclusive behind the scenes look at where the new "First Delivery" commercial came together and showed the full commercial for the first time Monday ...

The company made significant strides in commercial execution and experienced ... Eliquis, Xtandi, Nurtec, and several others across various categories. In addition, Pfizer Inc.

New data-driven deployment of our commercial ... year-over-year operational growth, driven by strong commercial execution. Nurtec is a leader in the oral CGRP class used for treating and ...

Pfizer posted Q4 revenue of $17.76 billion, up 22% YoY, with strong sales from Paxlovid, Vyndaqel, and Eliquis. The company reaffirmed its 2025 revenue outlook.

Nurtec ODT/Vydura globally, up 39% operationally, driven primarily by strong demand in the U.S. and, to a much lesser extent, recent launches in international markets, partially offset by lower ...